Charitha Gowda1,2, Vincent Lo Re2,3,4. 1. Department of Pediatrics, The Ohio State College of Medicine, Columbus, OH, USA. 2. Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 3. Department of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 4. Center for AIDS Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Abstract
PURPOSE OF REVIEW: Direct-acting antiviral regimens for chronic hepatitis C virus (HCV) became available in 2014, and these highly curative therapies have the potential to reduce HCV-associated morbidity and mortality, decrease transmission, and eliminate HCV infection as a public health problem. This review summarizes the recommendations by the National Academies of Sciences, Engineering, and Medicine for a US strategy for HCV elimination. RECENT FINDINGS: To achieve proposed targets of reducing HCV incidence by 90% and decreasing HCV-related mortality by 60% by 2030, there is a critical need to improve HCV diagnosis and linkage to care; reduce HCV-related disease by antiviral treatment scale-up; reduce HCV incidence; and strengthen HCV surveillance to determine achievement of HCV elimination targets over time. SUMMARY: While HCV elimination is feasible, success of this national effort will require ongoing collaboration and critical resource investment by key stakeholders, including medical and public health communities, legislators, community organizers, and patient advocates.
PURPOSE OF REVIEW: Direct-acting antiviral regimens for chronic hepatitis C virus (HCV) became available in 2014, and these highly curative therapies have the potential to reduce HCV-associated morbidity and mortality, decrease transmission, and eliminate HCV infection as a public health problem. This review summarizes the recommendations by the National Academies of Sciences, Engineering, and Medicine for a US strategy for HCV elimination. RECENT FINDINGS: To achieve proposed targets of reducing HCV incidence by 90% and decreasing HCV-related mortality by 60% by 2030, there is a critical need to improve HCV diagnosis and linkage to care; reduce HCV-related disease by antiviral treatment scale-up; reduce HCV incidence; and strengthen HCV surveillance to determine achievement of HCV elimination targets over time. SUMMARY: While HCV elimination is feasible, success of this national effort will require ongoing collaboration and critical resource investment by key stakeholders, including medical and public health communities, legislators, community organizers, and patient advocates.
Entities:
Keywords:
US public health threats; elimination; hepatitis C
Authors: Parag Mahale; Eric A Engels; Ruosha Li; Harrys A Torres; Lu-Yu Hwang; Eric L Brown; Jennifer R Kramer Journal: Gut Date: 2017-06-20 Impact factor: 23.059
Authors: Anna S Lok; Raymond T Chung; Hugo E Vargas; Arthur Y Kim; Susanna Naggie; William G Powderly Journal: Ann Intern Med Date: 2017-10-17 Impact factor: 25.391
Authors: William N Southern; Mari-Lynn Drainoni; Bryce D Smith; Elisa Koppelman; M Diane McKee; Cindy L Christiansen; Allen L Gifford; Cindy M Weinbaum; Alain H Litwin Journal: Qual Manag Health Care Date: 2014 Jan-Mar Impact factor: 0.926
Authors: Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen Journal: JAMA Date: 2012-12-26 Impact factor: 56.272
Authors: Jason Grebely; Gregory J Dore; Sébastien Morin; Jürgen K Rockstroh; Marina B Klein Journal: J Int AIDS Soc Date: 2017-07-28 Impact factor: 5.396
Authors: H Nina Kim; Robin M Nance; Vincent Lo Re; Michael J Silverberg; Ricardo Franco; Timothy R Sterling; Edward R Cachay; Michael A Horberg; Keri N Althoff; Amy C Justice; Richard D Moore; Marina Klein; Heidi M Crane; Joseph A Delaney; Mari M Kitahata Journal: J Acquir Immune Defic Syndr Date: 2022-04-01 Impact factor: 3.771
Authors: Heather Bradley; Eric W Hall; Elizabeth M Rosenthal; Patrick S Sullivan; A Blythe Ryerson; Eli S Rosenberg Journal: Hepatol Commun Date: 2020-01-14